Effects of Acceptance and Commitment Care in the Treatment of Aplastic Anemia Patients with Recombinant Human Thrombopoietin
- PMID: 39772298
- PMCID: PMC11744385
- DOI: 10.5152/pcp.2024.24947
Effects of Acceptance and Commitment Care in the Treatment of Aplastic Anemia Patients with Recombinant Human Thrombopoietin
Abstract
Background: This study was designed to determine the effects of acceptance and commitment care in the treatment of aplastic anemia (AA) patients with recombinant human thrombopoietin (rhTPO).
Methods: The clinical records of 100 AA patients treated at our hospital from March 2021 to March 2023 were analyzed in the retrospective study. All patients received immunosuppressants and rhTPO. Among them, 46 patients who received routine care from March 2021 to March 2022 were allocated to the control group, and the other 54 patients who received acceptance and commitment care from April 2022 to March 2023 were assigned to the study group. The quality of life (QoL) of the 2 groups was assessed by the MOS 36-Item Short-Form Health Survey (SF-36) before care and after 3 months of care. Blood-related indicators after care were compared in 2 groups.
Results: Before care, no significant inter-group discrepancy was observed in SF-36 scores in all dimensions (P > .05); whereas after nursing, the SF-36 scores of both groups increased conspicuously in all dimensions (P < .001), especially the study group (P < .001). After care, no significant differences were observed in hemoglobin (Hb), platelet count (PLT), and white blood cell count (WBC) between the 2 groups (P > .05). A conspicuously lower overall response rate was observed in the control group in contrast to the study group (P = .044), and no significant inter-group discrepancy was found in the total incidence of adverse reactions (P = .506).
Conclusion: Acceptance and commitment care is conducive to the patients with AA treated by rhTPO, because it substantially improves the QoL of patients, without increasing adverse reactions, so it is worth promoting.
Conflict of interest statement
Figures

Similar articles
-
[Impact on platelet recovery of recombinant human thrombopoietin in severe aplastic anemia patients with allogeneic hematopoietic stem cell transplantation].Zhonghua Xue Ye Xue Za Zhi. 2018 Mar 14;39(3):207-211. doi: 10.3760/cma.j.issn.0253-2727.2018.03.007. Zhonghua Xue Ye Xue Za Zhi. 2018. PMID: 29562465 Free PMC article. Chinese.
-
[Evaluation of the efficacy of cyclosporin A combined with recombined human thrombopoietin for treating patients with non-severe aplastic anemia].Zhonghua Xue Ye Xue Za Zhi. 2020 Aug 14;41(8):637-642. doi: 10.3760/cma.j.issn.0253-2727.2020.08.004. Zhonghua Xue Ye Xue Za Zhi. 2020. PMID: 32942816 Free PMC article. Chinese.
-
Recombinant Human Thrombopoietin Promotes Platelet Engraftment in Severe Aplastic Anemia Patients Following Treatment With Haploid Hematopoietic Stem Cell Transplantation using Modified Post-Transplantation Cyclophosphamide.Transplant Cell Ther. 2024 May;30(5):500-509. doi: 10.1016/j.jtct.2024.02.023. Epub 2024 Mar 4. Transplant Cell Ther. 2024. PMID: 38447750
-
[Effect of Recombinant Human Thrombopoietin on Platelet Reconstitution after Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma].Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2024 Apr;32(2):505-511. doi: 10.19746/j.cnki.issn.1009-2137.2024.02.028. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2024. PMID: 38660859 Chinese.
-
Efficacy and Safety of Recombinant Human Thrombopoietin on Sepsis Patients With Thrombocytopenia: A Systematic Review and Meta-Analysis.Front Pharmacol. 2020 Jun 24;11:940. doi: 10.3389/fphar.2020.00940. eCollection 2020. Front Pharmacol. 2020. PMID: 32714186 Free PMC article.
References
LinkOut - more resources
Full Text Sources
Miscellaneous